BRAF and non-small cell lung carcinoma: Mutations in BRAF, which encodes serine/threonine kinase in the RAS-MAPK signaling pathway, are present in approximately 2–4% of NSCLC, mainly in lung adenocarcinoma, and the V600E corresponds to approximately 30% of them [60], in which case the first line of treatment is vemurafenib and dabrafenib, which inhibit BRAF type I serine/threonine kinase by binding to its active site with greater affinity for the BRAF V600E mutation, not affecting other kinases [61].